Press Release: Nouscom : Nouscom's Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to 'Intercept' Cancer in Subjects with Lynch Syndrome

BASEL, Switzerland - 31st October 2023 - Nouscom, a clinical-stage immuno-oncology company developing off-the-shelf and personalized viral vector based cancer vaccines, today announced that promising interim data from a Phase 1b trial evaluating NOUS-209 in Lynch Syndrome (LS) carriers was published in a Late-breaking Abstract and will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA.